Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 10, Pages e003066
Publisher
BMJ
Online
2021-10-12
DOI
10.1136/jitc-2021-003066
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
- (2020) Lauren Julia Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
- (2020) Douglas B Johnson et al. LANCET ONCOLOGY
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Dermatology Consultation Reduces Interruption of Oncologic Management Among Hospitalized Patients with Immune-related Adverse Events: A Retrospective Cohort Study
- (2019) Steven T. Chen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Review of cancer treatment with immune checkpoint inhibitors
- (2017) Christiane Thallinger et al. WIENER KLINISCHE WOCHENSCHRIFT
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Anti-PD1-induced psoriasis: a study of 21 patients
- (2016) J. Bonigen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer
- (2016) Saad A. Khan et al. JAMA Oncology
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
- (2012) Scott M. Hayter et al. AUTOIMMUNITY REVIEWS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started